Arbutus Biopharma (ABUS) Return on Equity (2016 - 2025)

Historic Return on Equity for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to 0.53%.

  • Arbutus Biopharma's Return on Equity rose 1400.0% to 0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53%, marking a year-over-year increase of 1400.0%. This contributed to the annual value of 0.69% for FY2024, which is 900.0% down from last year.
  • Arbutus Biopharma's Return on Equity amounted to 0.53% in Q3 2025, which was up 1400.0% from 0.67% recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Return on Equity ranged from a high of 0.44% in Q2 2022 and a low of 0.87% during Q1 2025
  • Its 5-year average for Return on Equity is 0.59%, with a median of 0.61% in 2021.
  • In the last 5 years, Arbutus Biopharma's Return on Equity surged by 13600bps in 2021 and then tumbled by -1900bps in 2025.
  • Arbutus Biopharma's Return on Equity (Quarter) stood at 0.51% in 2021, then grew by 3bps to 0.49% in 2022, then tumbled by -31bps to 0.65% in 2023, then fell by -6bps to 0.68% in 2024, then increased by 23bps to 0.53% in 2025.
  • Its Return on Equity was 0.53% in Q3 2025, compared to 0.67% in Q2 2025 and 0.87% in Q1 2025.